×
0 0 0.00831372549019603 0.018156862745098 0.110490196078431 0.165676470588235 0.151960784313725 0.143137254901961
Stockreport

Evolus investors frown as FDA declines to approve Botox rival [Reuters]

EVOLUS (EOLS)  More Company Research Source: Reuters
US:NASDAQ Investor Relations: us.evolis.com/investor-relations
PDF Evolus investors frown as FDA declines to approve Botox rival | Reuters 3 Min Read (Reuters) - U.S. health regulators on Wednesday declined to approve Evolus Inc’s rival product to Allergan Plc’s Botox, citing deficiencies related to the chemistry and manufacturing of its potential treatment for frown lines, sending its shares down as much as 35 percent. The deficiencies cited by the U.S. Food and Drug Administration were “manageable”, according to Chief Executive Officer David Moatazedi, who joined the company earlier this month after serving as U.S. head of Allergan’s medical aesthetics business. “They are all questions we have considered and contemplated prior to the response from the FDA,” Moatazedi said on a call with analysts, but refused to specify the exact questions asked by the FDA. The company said it was committed to getting its DWP-450, which is being developed to treat glabellar lines or frown lines in adult patients, to the market by spring 2019. Evolus expects to respo [Read more]

IMPACT SNAPSHOT EVENT TIME: EOLS
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS